Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Key Points

• Investors bought 4,063 put options on Xenon Wednesday — a 2,362% jump over the average daily volume of 165 puts — indicating unusually heavy bearish or hedging activity.
• Analysts show a consensus Buy rating with a consensus target price of $73.13, and several firms raised targets (Needham to $80, Morgan Stanley to $97) despite a lone sell from Weiss.
• Insiders have been net sellers, disposing of 296,707 shares worth $17.85 million in the past three months (recent individual sales at $60.11), leaving insiders with 4.07% ownership.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Investors bought 4,063 put options on the stock. This is an increase of 2,362% compared to the average daily volume of 165 put options.

Analysts Set New Price Targets

Several analysts have recently weighed in on XENE shares. Needham & Company LLC raised their price objective on shares of Xenon Pharmaceuticals from $58.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, March 9th. Bank of America restated a "buy" rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an "overweight" rating in a research report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $73.13.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, insider Andrea Difabio sold 2,607 shares of the firm's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $156,706.77. Following the sale, the insider owned 4,893 shares in the company, valued at approximately $294,118.23. This trade represents a 34.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christopher John Kenney sold 2,771 shares of the firm's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total transaction of $166,564.81. Following the sale, the insider owned 4,729 shares in the company, valued at approximately $284,260.19. This trade represents a 36.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 296,707 shares of company stock valued at $17,845,365 in the last three months. Company insiders own 4.07% of the company's stock.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Neo Ivy Capital Management purchased a new position in Xenon Pharmaceuticals in the 3rd quarter worth $2,001,000. JPMorgan Chase & Co. increased its position in shares of Xenon Pharmaceuticals by 11.3% in the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company's stock valued at $56,171,000 after acquiring an additional 142,452 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at about $5,342,000. HighVista Strategies LLC increased its position in shares of Xenon Pharmaceuticals by 80.2% in the third quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company's stock valued at $3,300,000 after acquiring an additional 36,570 shares during the period. Finally, Westfield Capital Management Co. LP increased its position in shares of Xenon Pharmaceuticals by 4.6% in the third quarter. Westfield Capital Management Co. LP now owns 1,206,066 shares of the biopharmaceutical company's stock valued at $48,424,000 after acquiring an additional 53,461 shares during the period. Hedge funds and other institutional investors own 95.45% of the company's stock.

Xenon Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ:XENE opened at $55.75 on Thursday. The stock has a market cap of $5.39 billion, a PE ratio of -12.79 and a beta of 0.74. The company's fifty day moving average is $53.53 and its 200 day moving average is $46.13. Xenon Pharmaceuticals has a 52 week low of $28.19 and a 52 week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.11). During the same period in the prior year, the firm posted ($0.84) EPS. Sell-side analysts anticipate that Xenon Pharmaceuticals will post -4.83 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.